Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Cerevel Therapeutics 针对帕金森氏病的 Tavapadon 的 3 期 TEMPO-3 试验的关键结果达到了主要终点,表明总体 “上线” 时间与安慰剂